Sinopharm Group (HKG:1099) reported a net profit attributable to the parent of 3.70 billion yuan for the first six months ended June 30, a 9.76% decline compared with the 4.10 billion yuan profit reported in the year-ago period, according to the company's interim report filed with the Hong Kong bourse Wednesday.
Earnings per share were 1.19 yuan per share, down from 1.32 yuan per share a year earlier.
Revenue of the pharmaceutical company fell to 294.73 billion yuan from 300.95 billion yuan in the prior-year period
Price (HKD): $17.98, Change: $+0.74, Percent Change: +4.29%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments